InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 2 February 2024

LEEP: This phase II trial is trying to determine the effectiveness of a targeted cancer drug (ribociclib) at slowing down the growth of prostate cancer cellsA Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer

Clinical summary

Summary

Participants will be assigned by chance to either continue normal care or take a tablet of the study medication (Ribociclib, taken orally) in addition to the usual care for the 21 days leading up to their prostatectomy. At each study visit participants will have various assessments such as blood testing, urine testing, scans, and questionnaire completion. A sample of prostate tissue will also be taken during surgery.

Conditions

This trial is treating patients with prostate cancer.

Cancer

Urinary System Cancers Genitourinary

Age

People18+

Phase

II

Trial Acronym

LEEP

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Cancer Australia

Scientific Title

A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer

Eligibility

Inclusion

 

1. People with localised prostate cancer and at least clinical stage T3a Or Gleason score of between 8 and 10 Or Preoperative PSA greater than or equal to 20 ng/ml AND planned for radical prostatectomy
2. Age 18 yrs or older
3. ECOG performance 0-1
4. Histological confirmation of prostate cancer via a pre-treatment diagnostic transrectal ultrasound (TRUS) biopsy.
5. Adequate bone marrow function with platelets greater than or equal to 100 x 109/L, neutrophils greater than or equal to 1.5 x 109/L and haemoglobin greater than or equal to 90 g/L;
6. Adequate hepatic function with serum total bilirubin less than or equal to 1.5 x upper limit of normal range and ALT/SGPT and SGOT/AST less than or equal to 2.5x upper limit of normal range, serum albumin > 25 g/L, alkaline phosphatase less than or equal to 5x upper limit of normal range, and INR less than or equal to 1.5
7. Adequate renal function (with calculated creatinine clearance >50 ml/min based on the Cockcroft-Gault method, 24hour urine or GFR scan) and serum creatinine less than or equal to 1.5 x Upper Limit of Normal range (ULN);
8. Serum calcium, potassium, phosphate and magnesium within normal range or corrected with supplements
9. Study treatment both planned and able to start within 7 days of enrolment.
10. Willing and able to comply with all study requirements, including treatment and biospecimen collection
11. Signed, written informed consent (main study and biospecimen banking)

Exclusion

 

1. Major surgery less than or equal to 2 weeks prior to enrolment or who have not recovered from side effects of such therapy. Transrectal ultrasound (TRUS) biopsy is not considered major surgery in this study.
2. Known hypersensitivity to the study drug or its excipients
3. Diarrhoea greater than or equal to CTCAE grade 2
4. Impaired cardiac function, including any one of the following:
a) History (or family history) of long QT syndrome
b) Ribociclib should be avoided in patients who already have or who are at significant risk of developing QTc prolongation. This includes patients with:
• long QT syndrome
• Mean QTcF greater than or equal to 450 msec on baseline ECG
• uncontrolled or significant cardiac disease including recent myocardial infarction,
• congestive heart failure, unstable angina and bradyarrhythmias
• electrolyte abnormalities
• clinically significant ECG abnormalities at clinical discretion

c) History of clinically manifested ischemic heart disease less than or equal to 6 months prior to study start
d) History of heart failure or left ventricular (LV) dysfunction (LVEF less than or equal to 50%)
e) Other clinically significant heart disease (e.g. uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
f) Clinically significant resting bradycardia (< 50 beats per minute)
g) Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTcF interval or inducing Torsades de Pointes and cannot be discontinued or switched to an alternative drug prior to commencing start of treatment.
h) Obligate use of a cardiac pacemaker
5. Patients who have received prior antineoplastic therapy for advanced disease.
6. Prior treatment with an CDK4/6 inhibitor
7. Patients who are currently receiving treatment with strong CYP3A4 inhibitors and cannot be discontinued or switched to an alternative drug prior to commencing start of treatment.
8. Patients receiving chronic or high dose corticosteroids therapy (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed)
9. Significant infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated.
10. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.

Inclusion

  • You are able to swallow medication by mouth.
  • Your cancer has not spread to other parts of the body.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.